PSCH News and Press, PowerShares S&P SmallCap Health Care Portfolio From 02/10/21

After a dramatic year of volatility, the U.S. stock market ended 2020 at record highs. Can this momentum continue this year? ESG investments clearly outperformed in 2020. 2021 should be a year of much better cash flow for companies. For further details see: A Stock Picke...

2020 was a busy year for global healthcare with unprecedented efforts to develop vaccines, treatments, and diagnostics for COVID-19. Deal flow in the sector continued to gain momentum in 2020, with M&A transactions and product licensing deals totalling five-year highs as large-cap...

In each of the past three calendar years, small cap stocks in the U.S. have lagged their large cap counterparts by roughly 6-7% per year. This trend accelerated even more dramatically in the first quarter of 2020 as small caps underperformed large caps by over 10%-a magnitude larger than any q...

Background Information This presentation was done to derive portfolios through COVID-19 and the path towards recovery. Feel free to leave comments down below if there are any questions regarding our analyses and assumptions. Executive Summary Given the current situation with ...

Behaviour is the mirror in which everyone shows their image. - Johann Wolfgang Von Goethe The popular theory goes that the defensive sectors only come to the party when the going gets tough and the economic cycle turns; well, there’s no arguing with that in Q1-20, where one saw the ...

By Vinay Thapar and Frank Caruso US healthcare is always a political hot potato, and volatility is expected to rise as the November elections approach. But investors can find good opportunities in the sector in companies with strong long-term business drivers that are relatively immune to ...

(Source - Pexels/Pixbay ) It is widely believed that the Healthcare sector is a safe sector in a recessionary environment because "people always need medical treatment." While that is historically true, it seems that many investors are underweighting the substantial risks in the sector. H...

By Andy Acker, CFA & Luyi Guo, Ph.D., CFA & Rich Carney, CFA Last week, the Trump administration abandoned plans to overhaul drug rebates in Medicare while a federal judge ruled against listing prescription drug prices in TV ads. But U.S. drug reform is far from over, with implica...

By Stephen H. Dover, Executive Vice President, Head of Equities; Aman Gupta, Portfolio Manager, Research Analyst, Franklin Mutual Series; Brian DeChristopher, Research Analyst, Franklin Equity Group; Evan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group; Krzysz...

By Tony DeSpirito Markets tend to focus on one risk at a time, and it’s fragile U.S.-China relations that are front and center now. New blog contributor Tony DeSpirito offers up two potential takeaways for equity investors. Headlines over the U.S.-China trade dispute have been p...